Stonegate Investment Group LLC Trims Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stonegate Investment Group LLC reduced its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 4.5% during the 4th quarter, HoldingsChannel reports. The firm owned 3,276 shares of the pharmaceutical company’s stock after selling 154 shares during the period. Stonegate Investment Group LLC’s holdings in Vertex Pharmaceuticals were worth $1,333,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Arthur M. Cohen & Associates LLC increased its holdings in shares of Vertex Pharmaceuticals by 3.2% in the 4th quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock valued at $326,000 after acquiring an additional 25 shares during the period. Cooper Financial Group increased its holdings in shares of Vertex Pharmaceuticals by 1.0% in the 3rd quarter. Cooper Financial Group now owns 3,020 shares of the pharmaceutical company’s stock valued at $1,050,000 after acquiring an additional 29 shares during the period. Arjuna Capital grew its stake in Vertex Pharmaceuticals by 0.7% during the 3rd quarter. Arjuna Capital now owns 4,375 shares of the pharmaceutical company’s stock worth $1,521,000 after buying an additional 29 shares during the last quarter. West Family Investments Inc. grew its stake in Vertex Pharmaceuticals by 1.2% during the 2nd quarter. West Family Investments Inc. now owns 2,494 shares of the pharmaceutical company’s stock worth $878,000 after buying an additional 30 shares during the last quarter. Finally, FRG Family Wealth Advisors LLC grew its stake in Vertex Pharmaceuticals by 0.9% during the 3rd quarter. FRG Family Wealth Advisors LLC now owns 3,292 shares of the pharmaceutical company’s stock worth $1,145,000 after buying an additional 30 shares during the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Vertex Pharmaceuticals

In related news, Chairman Jeffrey M. Leiden sold 6,648 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $419.07, for a total value of $2,785,977.36. Following the completion of the transaction, the chairman now owns 2,423 shares in the company, valued at approximately $1,015,406.61. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares in the company, valued at approximately $23,755,762.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Chairman Jeffrey M. Leiden sold 6,648 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $419.07, for a total value of $2,785,977.36. Following the sale, the chairman now owns 2,423 shares of the company’s stock, valued at $1,015,406.61. The disclosure for this sale can be found here. Insiders sold a total of 19,029 shares of company stock worth $7,989,227 in the last 90 days. Corporate insiders own 0.40% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $409.42 on Wednesday. The stock has a market cap of $105.76 billion, a PE ratio of 29.48, a price-to-earnings-growth ratio of 2.29 and a beta of 0.35. The business has a 50-day simple moving average of $421.74 and a 200-day simple moving average of $392.87. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a 52-week low of $313.47 and a 52-week high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last announced its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The firm had revenue of $2.52 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the previous year, the business earned $3.33 EPS. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Wall Street Analyst Weigh In

VRTX has been the topic of several research analyst reports. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 6th. Truist Financial boosted their target price on Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Canaccord Genuity Group restated a “sell” rating and set a $379.00 target price (up from $332.00) on shares of Vertex Pharmaceuticals in a research note on Wednesday, January 24th. JPMorgan Chase & Co. boosted their target price on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Finally, HC Wainwright boosted their target price on Vertex Pharmaceuticals from $397.00 to $457.00 and gave the stock a “buy” rating in a research note on Tuesday, February 6th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $420.48.

Check Out Our Latest Report on VRTX

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Featured Articles

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.